<DOC>
	<DOCNO>NCT00904735</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , hydroxyurea , work different way stop growth tumor cell , either kill cell stop dividing . Imatinib mesylate may stop growth tumor cell block enzymes need cell growth . It yet know whether hydroxyurea effective give alone together imatinib mesylate treat patient meningioma . PURPOSE : This randomized phase II trial study well hydroxyurea work compare give hydroxyurea together imatinib mesylate treat patient recurrent progressive meningioma .</brief_summary>
	<brief_title>Hydroxyurea With Without Imatinib Mesylate Treating Patients With Recurrent Progressive Meningioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess progression-free survival patient recurrent progressive meningioma treat hydroxyurea v without imatinib mesylate surgery radiotherapy . Secondary - Determine overall survival , response rate patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients stratify accord WHO grade ( I vs II-III ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral hydroxyurea twice daily oral imatinib mesylate daily absence disease progression unacceptable toxicity . - Arm II : Patients receive oral hydroxyurea twice daily absence disease progression unacceptable toxicity . After completion study therapy , patient follow 1 year .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed meningioma WHO grade IIII Recurrent progressive disease prior surgery radiotherapy , radiosurgery Not amenable surgery No optic nerve sheet tumor neurofibromatosis type II No known brain metastasis PATIENT CHARACTERISTICS : WHO performance status 02 ANC &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin ≥ 9 mg/dL ( transfusion allow ) Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) SGOT SGPT &lt; 2.5 time ULN Creatinine &lt; 1.5 time ULN Negative pregnancy test Fertile patient must use effective barrier method contraception 3 month completion study therapy No second malignancy No known chronic liver disease ( i.e. , active hepatitis , cirrhosis ) No know HIV infection No significant history noncompliance medical regimen inability grant reliable informed consent PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent enzymeinducing antiepileptic drug No concurrent therapeutic anticoagulation warfarin ( e.g. , Coumadin® ) Lowmolecular weight heparin ( e.g. , Lovenox ) heparin allow Minidose Coumadin® ( e.g. , 1 mg QD ) allow prophylaxis central venous catheter thrombosis , discretion treat physician No concurrent acetaminophen ( Efferalgan® , Tachipirina® ) allow imatinib mesylate administration No concurrent anticancer agent , include chemotherapy biological agent No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>adult grade I meningioma</keyword>
	<keyword>adult grade II meningioma</keyword>
	<keyword>adult anaplastic meningioma</keyword>
	<keyword>adult papillary meningioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
</DOC>